NCT07890571|Not Yet Recruiting
Loading search results
Sponsor study identifier
interventional
100
1 country
1
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
August 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
September 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Melasma is a common acquired hyperpigmentation disorder that significantly affects quality of life. Various topical agents are used in its treatment, including Vitamin C and Niacinamide, both of which possess depigmenting properties. This randomized controlled trial aims to compare the efficacy of topical Vitamin C and topical Niacinamide in patients with melasma. A total of 100 patients will be enrolled and randomly allocated into two groups. Treatment efficacy will be assessed using the Melasma Area and Severity Index (MASI) score after 12 weeks of therapy. The findings of this study may help determine the more effective topical treatment option for melasma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 16, 2026
Actual (reported)October 22, 2026
Actual (reported)November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
August 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
September 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
change in MASI score
change in melasma area and severity index (MASI) score from baseline to the end of the treatment period in the participants treated with topical vitamin c compared with those with topical niacinamide
Baseline to the end of the treatment period (12 weeks)
participants assigned to this intervention will receive 10% topical ascorbic acid formulations for treatment of melasma. The formulations will be applied according to the frequency and duration specified in the study protocol.
participants assigned to this intervention will receive a topical 10 % niacinamide formulation for the treatment of melasma. The formulation will be applied according to the frequency and duration specified in the study protocol.
Pak Emirates Military Hospital
Rawalpindi, Punjab Province, 46000, Pakistan
First Submitted
October 16, 2026
First Posted
October 22, 2026
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
August 1, 2027
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
September 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 22, 2026
Record last verified: 2026-10
individual participation data will not be shared with other researhers.Only aggregates study results may be published while maintaining participant confidentiality.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: